Country
Clinical Trials in Rwanda
Studies with at least one site in Rwanda. Open a trial for its sites in Rwanda, who to contact and who can take part.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 23HIV (Human Immunodeficiency Virus), HPV
Feasibility Study Comparing One vs Two Probes for TA Among Cervical Cancer Screen Positive WLWH in C1001P-CS5 Rwanda
Cervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general…
- Conditions
- HIV (Human Immunodeficiency Virus), HPV, Cervical Precancer
- Trial name
- NCT07390916
- Testing
- Thermal ablation (TA) with 1 probe, Thermal ablation (TA) with 2 probes
- Where
- Rwanda
- Volunteers
- 300 people
- Sponsor
- Fred Hutchinson Cancer Center
Uncomplicated Plasmodium Falciparum Malaria
Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort C2)
This was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
- Trial name
- PLATINUM (NCT07811908)
- Testing
- KAE609, SoC (Coartem), KLU156
- Where
- 13 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 120 people
- Sponsor
- Novartis Pharmaceuticals
Fetal Weight, Pregnancy
Prospective Evaluation of an AI Diagnostic Ultrasound Tool for Fetal Weight Estimation
Purpose: The primary objective of this study is to assess the diagnostic accuracy of an AI-enabled ultrasound tool for estimating fetal weight Participants: 1,000 pregnant individuals Procedures (methods): This prospective…
- Conditions
- Fetal Weight, Pregnancy, Machine Learning, Pregnancy - Prenatal Testing
- Trial name
- krittenhouse (NCT07661433)
- Testing
- AI ultrasound diagnostic tool for fetal weight estimation
- Where
- 6 sites in United States, Canada and 2 more
- Volunteers
- 1,000 people
- Sponsor
- University of North Carolina, Chapel Hill
Heart Failure
Heart Failure Self Care Education in Rwanda
In Rwanda, patients with heart failure may have low health education about their condition. Heart failure care requires active patient involvement.
- Trial name
- NCT07722468
- Testing
- HF Education
- Where
- Rwanda
- Volunteers
- 400 people
- Sponsor
- Boston Medical Center
Pregnant Women
Association of Gestational Cardiovascular Health With Pregnancy Outcomes
Pregnancy is a critical period for cardiovascular health risk assessment and interventions to reduce the incidence of cardiovascular disease in both mother and child generations.
- Trial name
- NCT05776082
- Testing
- Questionnaire survey and specimen collection
- Where
- 3 sites in China, Rwanda
- Volunteers
- 5,000 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Breast Cancer, Cervical Cancer
Breast and Cervical Cancer Stigma in Rwanda
This study aims to assess breast and cervical cancer stigma and pilot a multi-modal intervention to mitigate stigma among patients, caregivers, and community health workers in Rwanda.
- Trial name
- NCT07663006
- Testing
- Behavioral: RISE Intervention, Behavioral: CHW Educational Intervention
- Where
- 2 sites in Rwanda
- Volunteers
- 1,116 people
- Sponsor
- Dana-Farber Cancer Institute
Sepsis
Smart Discharges for Older Children
This study is an observational multi-country cohort study that aims to build algorithms that can identify children between 5 and 16 years of age admitted for proven or suspected sepsis who are at risk of mortality after they are…
- Trial name
- NCT07629154
- Testing
- No Intervention: Observational Cohort
- Where
- 7 sites in United States, Canada and 3 more
- Volunteers
- 4,000 people
- Sponsor
- University of British Columbia
Breast Cancer, Early Detection of Cancer
Strategies to Decentralize Breast Ultrasound in Rwanda
Diagnosing breast cancer early is critical to reduce preventable breast cancer deaths in sub-Saharan Africa. This can be done in part through increasing patients' access to breast ultrasound, which is essential for evaluating…
- Conditions
- Breast Cancer, Early Detection of Cancer, Ultrasonography
- Trial name
- NCT06812208
- Testing
- Teleultrasound with Philips Lumify ultrasound probes and Reacts software, Asynchronous virtual feedback
- Where
- Rwanda
- Volunteers
- 1,792 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Medication Adherence, Breast Cancer
Adjuvant Endocrine Therapy Adherence Intervention Pilot in Rwanda
This study aims to evaluate a multi-modal intervention designed to improve adherence to adjuvant endocrine therapy (AET) among patients with ER-positive breast cancer in Rwanda.
- Trial name
- NCT07562399
- Testing
- Educational video, Symptom monitoring card, Text reminders
- Where
- 4 sites in United States, Rwanda
- Volunteers
- 224 people
- Sponsor
- Dana-Farber Cancer Institute
Surgical Site Infection Following Cesarean Delivery, Cesarean Section Complications
Evaluation of an mHealth-CHW Tool for Post-c-section Follow-up in Rural Rwanda
Cesarean sections (c-sections) are one of the most common surgical procedures done globally. However, there has been an increase in the number of c-section related complications.
- Trial name
- NCT07369700
- Testing
- mHealth Community Health Worker Intervention for post-cesarean follow up
- Where
- Rwanda
- Volunteers
- 1,350 people
- Sponsor
- University of North Carolina, Chapel Hill
Completed, with results posted
All –Infant, Low Birth Weight
Household Air Pollution and Health: A Multi-country LPG Intervention Trial
This study is a randomized controlled trial of liquefied petroleum gas (LPG) stove and fuel distribution in 3,200 households in four countries (India, Guatemala, Peru, and Rwanda).
- Trial name
- HAPIN (NCT02944682)
- Testing
- Liquefied petroleum gas (LPG) cookstove
- Where
- 4 sites in Guatemala, India and 2 more
- Volunteers
- 6,704 people
- Sponsor
- Emory University
Severe Malaria
To Evaluate Efficacy, Safety, Tolerability and PK of Intravenous Cipargamin in Participants With Severe Plasmodium Falciparum Malaria
The purpose of this study was to identify the safe and effective dose of intravenous cipargamin in participants with moderately severe and severe malaria.
- Trial name
- NCT04675931
- Testing
- Cipargamin, IV Artesunate, Coartem
- Where
- 9 sites in Burkina Faso, Côte d’Ivoire and 5 more
- Volunteers
- 254 people
- Sponsor
- Novartis Pharmaceuticals
Healthy
Safety, Tolerability and Immunogenicity Study of Different Vaccine Regimens of Trivalent Ad26.Mos.HIV or Tetravalent Ad26.Mos4.HIV Along With Clade C Glycoprotein (gp)140 in Healthy Human Immunodeficiency Virus (HIV)-Uninfected Adults
The purpose of this study is to assess the safety/tolerability of the 2 different vaccine regimens of priming with trivalent Ad26.Mos.HIV and boosting with trivalent Ad26.Mos.HIV and Clade C gp140 plus adjuvant or priming with…
- Trial name
- NCT02788045
- Testing
- Ad26.Mos.HIV, Ad26.Mos4.HIV, Clade C gp140
- Where
- 10 sites in United States, Rwanda
- Volunteers
- 201 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Healthy
A Safety, Tolerability and Immunogenicity Study of 2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Tetravalent Ad26.Mos4.HIV Along With Either Clade C gp140 Plus Adjuvant OR With a Combination of Mosaic and Clade C gp140 Plus Adjuvant in Healthy HIV Uninfected Adults
The primary purpose of this study is to assess safety/tolerability of the different vaccine regimens and of a late boost vaccination; and to assess envelope (Env)-binding antibody (Ab) responses of the 2 different vaccine…
- Trial name
- IPCAVD-012 (NCT02935686)
- Testing
- Ad26.Mos4.HIV, Clade C gp140 plus adjuvant, Clade C gp140/Mosaic gp140 plus adjuvant
- Where
- 13 sites in United States, Kenya and 1 more
- Volunteers
- 155 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.
Healthy
Safety, Tolerability, and Immunogenicity Study of Homologous Ad26 Mosaic Vector Vaccine Regimens or Heterologous Ad26 Mosaic and MVA Mosaic Vector Vaccine Regimens With Glycoprotein 140 (gp140) for Human Immunodeficiency Virus (HIV) Prevention
The purpose of this study is to assess the safety and tolerability of various regimens containing adenovirus serotype 26-Mosaic -Human Immunodeficiency Virus (Ad26.Mos.HIV), Modified Vaccinia Ankara (MVA)-Mosaic, and/or HIV type…
- Trial name
- NCT02315703
- Testing
- Ad26.Mos.HIV, MVA-Mosaic, gp140 DP Low-dose
- Where
- 12 sites in United States, Rwanda and 3 more
- Volunteers
- 393 people, healthy volunteers welcome
- Sponsor
- Janssen Vaccines & Prevention B.V.